TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) S.A.E. Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E. Stock
Equities
RMDA
EGS381B1C015
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.51 EGP | -1.18% |
|
-3.83% | +52.12% |
| Sales 2024 * | 2.92B 60.72M | Sales 2025 * | 3.21B 66.87M | Capitalization | 3.74B 77.86M |
|---|---|---|---|---|---|
| Net income 2024 * | 361M 7.51M | Net income 2025 * | 485M 10.09M | EV / Sales 2024 * | 1.65 x |
| Net Debt 2024 * | 1.07B 22.2M | Net Debt 2025 * | 766M 15.94M | EV / Sales 2025 * | 1.4 x |
| P/E ratio 2024 * |
8.45
x | P/E ratio 2025 * |
7.69
x | Employees | - |
| Yield 2024 * |
2.81% | Yield 2025 * |
4.23% | Free-Float | 50.28% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -1.18% | ||
| 1 week | -3.83% | ||
| Current month | -3.46% | ||
| 1 month | -13.45% | ||
| 3 months | +32.11% | ||
| 6 months | +60.59% | ||
| Current year | +52.12% |
1 week
2.43
2.69
1 month
2.432.95
Current year
1.653.40
1 year
1.313.40
3 years
1.063.40
5 years
1.063.40
10 years
1.063.40
| Managers | Title | Age | Since |
|---|---|---|---|
Amr Morsy
CEO | Chief Executive Officer | - | 10-12-31 |
Mahmoud Fayek
DFI | Director of Finance/CFO | - | 18-12-31 |
Rania Farouk
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Farida Khamis
BRD | Director/Board Member | - | 19-12-31 |
| Director/Board Member | 65 | 18-12-31 | |
| Director/Board Member | - | 10-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-22 | 2.51 | -1.18% | 4,664,347 |
| 24-04-21 | 2.54 | +2.01% | 3,522,580 |
| 24-04-18 | 2.49 | -4.60% | 8,651,035 |
| 24-04-17 | 2.61 | -1.14% | 8,922,104 |
| 24-04-16 | 2.64 | +1.15% | 4,919,411 |
End-of-day quote Egyptian Exchange, April 21, 2024
More quotes
Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents S.A.E (RAMEDA) specializes in the manufacture and marketing of generic pharmaceutical products. The products include antibiotics, vitamins, analgesics, medicines for ophthalmological care, gastrointestinal, dermatological and cardiovascular diseases, food supplements, medical devices and veterinary products.
Sector
Pharmaceuticals
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
2.51
EGP
Average target price
3.472
EGP
Spread / Average Target
+38.31%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +52.12% | 77.7M | |
| +25.46% | 659B | |
| +26.70% | 557B | |
| -4.86% | 359B | |
| +16.44% | 322B | |
| +8.34% | 297B | |
| +6.36% | 215B | |
| +7.27% | 210B | |
| -6.30% | 200B | |
| -8.79% | 149B |
- Stock Market
- Equities
- RMDA Stock
